

: Gastric bypass surgery; Gastrointestinal anatomy; Pharmacokinetics; Small stomach pouch

Gastric bypass surgery, a widely employed bariatric procedure for the treatment of morbid obesity, has transformative e ects on the anatomy and physiology of the gastrointestinal tract. Beyond its primary objective of weight loss, this surgical intervention induces signi cant changes in the absorption, distribution, metabolism, and elimination of drugs fundamental components of pharmacokinetics. As an increasing number of individuals undergo gastric bypass surgery, understanding the intricate interplay between this procedure and drug pharmacokinetics becomes paramount for ensuring optimal therapeutic outcomes and patient safety [1]. e surgical technique involves the creation of a small stomach pouch and the rerouting of the small intestine, resulting in alterations to the traditional pathway of nutrient absorption and digestion. While the implications for weight management are well-documented, the consequences for drug absorption kinetics are an emerging area of interest. modi ed gastrointestinal anatomy prompts a reassessment of drug bioavailability, with potential rami cations for the timing and extent of drug entry into the systemic circulation [2].

Gastric bypass surgery, a type of weight loss surgery, can have signi cant e ects on drug pharmacokinetics. e surgery involves creating a small stomach pouch and rerouting the small intestine, leading to changes in the absorption and metabolism of medications. Here are some general outcomes and considerations

Altered absorption

e rearrangement of the digestive tract can a ect the absorption of drugs. Medications that are primarily absorbed in the stomach or upper part of the small intestine may be a ected more than those absorbed in the lower part of the small intestine [3,4].

Changes in bioavailability

Bioavailability refers to the proportion of a drug that enters the systemic circulation when introduced into the body and is made

Potential for drug interactions

Gastric bypass surgery can also a ect the absorption and metabolism of multiple drugs simultaneously, potentially leading to altered drug interactions. Healthcare providers need to consider these interactions when prescribing medications for patients who have undergone gastric bypass surgery [11].

C

As healthcare professionals navigate the complexities of managing medications in individuals who have undergone gastric bypass surgery, it is imperative to strike a balance between achieving therapeutic e cacies and mitigating the risk of adverse e ects. is review aims to consolidate existing knowledge on the outcomes of gastric bypass surgery on drug pharmacokinetics, providing a foundation for informed clinical decision-making and prompting further research to re ne our understanding of this intricate interplay.

References

- 1. Haslam DW, James WP (2005) Obesity. Lancet. 366: 1197-11209.
- Caballero B (2007) The global epidemic of obesity: an overview. Epidemiol Rev. 29: 1-5.

- Morrish GA, Pai MP, Green B (2011) The efects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol. 7: 697-706.
- Shields M, Carroll MD, Ogden CL (2011) Adult obesity prevalence in Canada and the United States. NCHS Data Brief. 56: 1-8.
- Anonymous (2006) Obesity and overweight. Fact Sheet 311. In: Organization WH, editor. World health organization. Edition. World Health Organization.
- Vincent HK, Heywood K, Connelly J, Hurley RW (2012) Obesity and weight loss in the treatment and prevention of osteoarthritis. NCHS PM slotualTex4: S59-672.0